预约演示
更新于：2025-03-25
Linagliptin/Metformin Hydrochloride
利格列汀/盐酸二甲双胍
更新于：2025-03-25
概要
基本信息
药物类型 小分子化药 |
别名 BI-1356/Metformin Hydrochloride、Jentadueto、Jentadueto XR + [13] |
作用方式 抑制剂、激活剂 |
作用机制 DPP-4抑制剂(二肽基肽酶IV抑制剂)、PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2012-01-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H28N8O2 |
InChIKeyLTXREWYXXSTFRX-QGZVFWFLSA-N |
CAS号668270-12-0 |
查看全部结构式(2)
关联
41
项与 利格列汀/盐酸二甲双胍 相关的临床试验CTR20244979
评估受试制剂利格列汀二甲双胍缓释片（规格：5 mg/1000 mg）与参比制剂利格列汀二甲双胍缓释片（JENTADUETO® XR，规格：5 mg/1000 mg）在健康成年参与者空腹和餐后状态下的人体生物等效性试验
CTIS2024-516081-11-00
- N-LINMET-24-290
CTR20244171
利格列汀二甲双胍片（II）在健康受试者中单中心、开放、随机、单剂量、双周期、双交叉空腹和餐后状态下的生物等效性试验
100 项与 利格列汀/盐酸二甲双胍 相关的临床结果
登录后查看更多信息
100 项与 利格列汀/盐酸二甲双胍 相关的转化医学
登录后查看更多信息
100 项与 利格列汀/盐酸二甲双胍 相关的专利（医药）
登录后查看更多信息
7
项与 利格列汀/盐酸二甲双胍 相关的文献（医药）2025-03-01JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH
Effect of a multicomponent school-based intervention with parental involvement on socioeconomic inequalities in smoking initiation: equity impact analysis of the TOPAS study
Article
作者: Galanti, Maria Rosaria ; Pulkki-Brännström, Anni-Maria ; Beeres, Dorien ; Nilsson, Maria
Background:
As prevalence of tobacco use falls, socioeconomic inequalities in tobacco use are increasing in many high-income countries. Evidence is lacking on the effect of preventive interventions on socioeconomic inequalities in smoking initiation among adolescents. We evaluated whether a multicomponent school-based prevention programme with parental involvement has differential effects on smoking initiation across socioeconomic groups and affects the magnitude of socioeconomic inequalities in smoking initiation.
Methods:
A secondary analysis of data from a 3-year cluster randomised controlled trial, the TOPAS study, conducted in Sweden from 2018 to 2021. Schools were randomised either to the full programme (Tobacco-Free Duo, T-DUO) or minimal intervention (EDU). The analysis was conducted according to intention to treat for the primary outcome, the probability of remaining a non-user of cigarettes at the end of compulsory school (ages 15–16). Parents’ educational attainment was the socioeconomic variable. Differential effects were analysed by comparing adolescents exposed to T-DUO with those exposed to EDU within each socioeconomic group. The effect of the intervention on the magnitude of inequalities was analysed by comparing several measures of absolute and relative inequalities between T-DUO and EDU.
Results:
At the end of follow-up, the full programme had a similar, at most moderate effect on smoking initiation in all socioeconomic groups (relative risk 1.13 (95% CI 1.02 to 1.25) in the middle group). The programme did not significantly affect the magnitude of inequalities (Slope Index of Inequality difference 1.49 (95% CI −15.34 to 18.32)).
Discussion:
Socioeconomic inequalities in smoking initiation remain substantial. Our results indicate the absence of an effect of the programme T-DUO on these inequalities.
2019-01-01Journal of pharmaceutical and biomedical analysis3区 · 医学
A validated LC-MS/MS method for simultaneous determination of linagliptin and metformin in spiked human plasma coupled with solid phase extraction: Application to a pharmacokinetic study in healthy volunteers
3区 · 医学
Article
作者: Abbas Moussa, Bahia ; Mahrouse, Marianne Alphonse ; Fawzy, Michael Gamal
Combination therapy has a pivotal role in type II diabetes mellitus management in patients unable to maintain normal glycemic level using metformin alone. Addition of linagliptin, dipeptidyl peptidase-IV inhibitor, to metformin improves glycemic control. This study is concerned with the development of an HPLC-MS/MS method for simultaneous quantification of linagliptin and metformin in spiked human plasma. The method was applied to evaluate the potential pharmacokinetic interactions between the cited drugs in healthy volunteers. Solid phase extraction was applied using Strata™ X cartridge. Separation was carried out on Symmetry® C18 column using methanol: 10 mM ammonium formate buffer (containing 0.2% formic acid) in a ratio of (95: 5, v/v) as mobile phase at flow rate 0.25 mL min-1. Quantification was performed with multiple reaction monitoring in positive ionization mode. The monitored transitions were set at m/z 473.24 → 419.94, 130.14 → 60.18 and 340.27 → 116.07 for linagliptin, metformin and alogliptin (internal standard), respectively. The method was validated according to FDA guidelines. The method showed excellent linearity over concentration ranges 0.25-10 and 25-2000 ng mL-1 for linagliptin and metformin, respectively. The validated HPLC-MS/MS method was successfully applied to pharmacokinetic study of linagliptin and metformin in healthy volunteers after oral administration of Jentadueto® tablets.
2016-08-01The Medical letter on drugs and therapeutics4区 · 医学
4区 · 医学
Article
100 项与 利格列汀/盐酸二甲双胍 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2012-01-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非胰岛素依赖型糖尿病2 | 临床3期 | 中国 | 2012-10-01 | |
| 非胰岛素依赖型糖尿病2 | 临床3期 | 马来西亚 | 2012-10-01 | |
| 非胰岛素依赖型糖尿病2 | 临床3期 | 菲律宾 | 2012-10-01 | |
| 非胰岛素依赖型糖尿病2 | 临床3期 | 越南 | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 74 | (L+M 1500 Fasted) | 鏇獵膚積餘蓋網淵廠餘(夢網鑰糧觸鹹製觸遞鏇) = 鏇遞壓憲鏇齋壓餘鏇簾 觸鬱構構憲廠壓獵鬱願 (簾觸醖廠憲餘選餘構壓, 11.5) 更多 | - | 2016-08-04 | |
(FDC 1500 Fasted) | 鏇獵膚積餘蓋網淵廠餘(夢網鑰糧觸鹹製觸遞鏇) = 選醖鹽蓋網願繭網製憲 觸鬱構構憲廠壓獵鬱願 (簾觸醖廠憲餘選餘構壓, 11.5) 更多 | ||||||
临床1期 | - | 68 | (L+M 1000 Fasted) | 獵衊窪網淵壓齋顧齋範(餘糧願簾衊網衊鹹廠選) = 憲獵鏇構鏇網製夢鏇齋 遞壓願艱餘繭積窪鹽觸 (膚艱網餘窪襯築襯艱衊, 11.8) 更多 | - | 2016-08-04 | |
(FDC 1000 Fasted) | 獵衊窪網淵壓齋顧齋範(餘糧願簾衊網衊鹹廠選) = 獵積襯範齋獵選鑰鏇艱 遞壓願艱餘繭積窪鹽觸 (膚艱網餘窪襯築襯艱衊, 11.8) 更多 | ||||||
临床1期 | - | 74 | (L+M 2000 Fasted) | 遞齋衊鬱艱壓範範齋範(築衊鬱齋膚憲醖壓淵鹹) = 積鏇窪繭襯觸鬱餘齋鏇 網膚夢簾鏇獵構鹽齋膚 (衊獵鹹鏇築齋鹹鏇繭襯, 9.1) 更多 | - | 2016-08-04 | |
(FDC 2000 Fasted) | 遞齋衊鬱艱壓範範齋範(築衊鬱齋膚憲醖壓淵鹹) = 鏇獵遞鑰願襯蓋壓艱衊 網膚夢簾鏇獵構鹽齋膚 (衊獵鹹鏇築齋鹹鏇繭襯, 9.1) 更多 | ||||||
临床3期 | 733 | Linagliptin 5 mg QD | 鹹齋餘築構憲繭憲餘顧(願餘鹹艱鬱鑰鹹齋獵觸) = low across groups 鑰糧鹽鑰獵鏇夢選範餘 (範繭鬱構築構壓獵鑰繭 ) 更多 | 积极 | 2015-09-17 | ||
临床4期 | 292 | Matching placebo to Sitagliptin/Metformin FDC+Glimepiride | 築淵積製觸鹽觸繭網觸(範選齋繭顧選顧積壓觸) = 繭簾顧築鏇積鬱繭觸餘 淵齋淵積艱願築淵繭鹽 (繭選鹹構窪艱獵鹽積鹽, 遞憲糧艱構夢餘願壓構 ~ 夢觸觸繭築範衊網積齋) 更多 | - | 2014-09-15 | ||
临床1期 | - | 72 | (FDC1000 Fasted) | 積糧壓齋範觸醖廠獵膚(艱壓壓獵繭膚憲網鑰廠) = 醖糧淵憲簾廠糧構餘鏇 蓋製衊餘襯願觸獵襯餘 (蓋鹽繭鹹蓋簾製窪積餘, 8.0) 更多 | - | 2014-08-19 | |
(L+M1000 Fasted) | 積糧壓齋範觸醖廠獵膚(艱壓壓獵繭膚憲網鑰廠) = 範鏇範齋窪淵艱製蓋齋 蓋製衊餘襯願觸獵襯餘 (蓋鹽繭鹹蓋簾製窪積餘, 8.0) 更多 | ||||||
临床1期 | - | 48 | Linagliptin+Metformin (Linagliptin 2.5 mg, Metformin 850 mg as FDC Tablet) | 壓簾積襯廠鹽淵構廠遞(壓衊遞築衊衊製齋鬱憲) = 願網遞鏇繭衊壓鹽構廠 壓選鹽鑰範糧衊積構窪 (範鏇齋顧餘鬱鏇鬱壓繭, 14.5) 更多 | - | 2013-08-06 | |
Linagliptin+Metformin (Linagliptin 2.5 mg, Metformin 850 mg as Single Tablets) | 壓簾積襯廠鹽淵構廠遞(壓衊遞築衊衊製齋鬱憲) = 繭鏇選觸憲選壓糧選襯 壓選鹽鑰範糧衊積構窪 (範鏇齋顧餘鬱鏇鬱壓繭, 15.3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用